688356.SH
Jenkem Technology Co., Ltd.
SSE · Healthcare · Medical - Pharmaceuticals · CN
CNY 124.00
+15.52%Sep 14, 2026, 12:41 UTC
Jenkem Technology stated at its 2026 half-year results briefing that capacity utilization at its Panjin plant rose year over year and that it has begun stable supply of end products to some newly acquired customers.
Source:Sep 8, 2026, 08:54 UTC
Jiankai Technology director and CFO Han Lei plans to reduce his holdings by no more than 7,875 shares, representing no more than 0.013% of total share capital, through centralized bidding from October 9, 2026 to January 8, 2027.
Source:Aug 25, 2026, 08:16 UTC
Jiankai Technology announced the termination of its wholly-owned subsidiary Tianjin Jiankai's phase III clinical study of polyethylene glycol irinotecan (JK1201I) for relapsed or progressive extensive-stage small cell lung cancer, and will fully impair the capitalized R&D amount of 70.6411 million yuan, reducing its 2026 half-year total profit by the same amount.
Source:Aug 24, 2026, 08:36 UTC
Wu Kaiting, a shareholder holding more than 5% of Jiankai Technology, completed a reduction of 3% of the company's shares through centralized bidding and block trades between July 15 and August 24, 2026.
Source: